Literature DB >> 23871772

Hepatitis G virus/GBV-C in serum, peripheral blood mononuclear cells and bone marrow in patients with hematological malignancies.

Elżbieta Kisiel1, Kamila Caraballo Cortez, Agnieszka Pawełczyk, Iwona Bukowska Ośko, Natalia Kubisa, Tomasz Laskus, Marek Radkowski.   

Abstract

BACKGROUND: HGV/GBV-C is highly prevalent in the general population but its significance remains unclear. It is known that HGV/GBV-C is not primary hepatotropic and its replication was reported in PBMC, bone marrow and other tissues. To investigate a possible role of HGV/GBV-C 115 consecutive patients with hematological malignancies were analyzed for virus RNA presence and quasispecies composition in three compartments: serum, PBMC and bone marrow.
METHODS: RT-PCR was used to amplify 5'UTR HGV/GBV-C in serum, PBMC and bone marrow. Viral sequences obtained from three compartments were subjected for comparative molecular analysis performed by single strand conformational polymorphism (SSCP) and pyrosequencing.
RESULTS: HGV/GBV-C RNA was detected in 23 out of 115 (20.0%) patients, most often in bone marrow (18 patients), followed by PBMC (11 patients) and serum (10 patients). Differences in SSCP bands distribution corresponding to different viral variants and confirmed by direct sequencing were observed in three patients.
CONCLUSION: HGV/GBV-C infection is frequent in patients with hematological malignancies. Common detection of HGV/GBV-C in bone marrow supports the hypothesis that it is a major replication site of this virus.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bone marrow; Compartmentalization; HGV/GBV-C; Quasispecies

Mesh:

Substances:

Year:  2013        PMID: 23871772     DOI: 10.1016/j.meegid.2013.07.010

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  6 in total

Review 1.  Tropism of human pegivirus (formerly known as GB virus C/hepatitis G virus) and host immunomodulation: insights into a highly successful viral infection.

Authors:  Ernest T Chivero; Jack T Stapleton
Journal:  J Gen Virol       Date:  2015-02-09       Impact factor: 3.891

2.  Human Pegivirus infection and lymphoma risk and prognosis: a North American study.

Authors:  Angelo Fama; Jinhua Xiang; Brian K Link; Cristine Allmer; Donna Klinzman; Andrew L Feldman; Grzegorz S Nowakowski; Mark Liebow; Melissa C Larson; Matthew J Maurer; Stephen M Ansell; Anne J Novak; Yan W Asmann; Susan L Slager; Timothy G Call; Thomas M Habermann; James R Cerhan; Jack T Stapleton
Journal:  Br J Haematol       Date:  2018-05-29       Impact factor: 6.998

3.  Human pegivirus RNA is found in multiple blood mononuclear cells in vivo and serum-derived viral RNA-containing particles are infectious in vitro.

Authors:  Ernest T Chivero; Nirjal Bhattarai; Robert T Rydze; Mark A Winters; Mark Holodniy; Jack T Stapleton
Journal:  J Gen Virol       Date:  2014-03-25       Impact factor: 3.891

4.  Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis.

Authors:  Angelo Fama; Melissa C Larson; Brian K Link; Thomas M Habermann; Andrew L Feldman; Timothy G Call; Stephen M Ansell; Mark Liebow; Jinhua Xiang; Matthew J Maurer; Susan L Slager; Grzegorz S Nowakowski; Jack T Stapleton; James R Cerhan
Journal:  Clin Infect Dis       Date:  2020-08-22       Impact factor: 9.079

5.  Equine pegiviruses cause persistent infection of bone marrow and are not associated with hepatitis.

Authors:  Joy E Tomlinson; Raphael Wolfisberg; Ulrik Fahnøe; Himanshu Sharma; Randall W Renshaw; Louise Nielsen; Eiko Nishiuchi; Christina Holm; Edward Dubovi; Brad R Rosenberg; Bud C Tennant; Jens Bukh; Amit Kapoor; Thomas J Divers; Charles M Rice; Gerlinde R Van de Walle; Troels K H Scheel
Journal:  PLoS Pathog       Date:  2020-07-10       Impact factor: 6.823

Review 6.  Review of human pegivirus: Prevalence, transmission, pathogenesis, and clinical implication.

Authors:  Yaqi Yu; Zhenzhou Wan; Jian-Hua Wang; Xianguang Yang; Chiyu Zhang
Journal:  Virulence       Date:  2022-12       Impact factor: 5.882

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.